Hunan Er-Kang Pharmaceutical Co., Ltd

300267

CNE100001781

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 16/05/2024 am IST			5-day change	1st Jan Change
2.61 ^CNY	0.00%		-7.12%	-18.69%

26/04	Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24/04	Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Hunan Er-Kang Pharmaceutical Co., Ltd Approves 2022 Profit Distribution Plan

May 20, 2023 at 01:13 am IST

Hunan Er-Kang Pharmaceutical Co., Ltd, at its Annual General Meeting of 2022 held on 18 May 2023, approved 2022 profit distribution plan. The detailed profit distribution plan are as follows: Cash dividend/10 shares (tax included) of CNY 0.30000000.

Latest news about Hunan Er-Kang Pharmaceutical Co., Ltd

Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	24/04	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	22/23/22	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	27/23/27	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2022 Final Profit Distribution, Payable on 09 June 2023	03/23/03	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Approves 2022 Profit Distribution Plan	20/23/20	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2022	28/23/28	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	26/23/26	CI
ER-KANG Pharma Earmarks $140 Million for Lithium Carbonate Factory; Shares Gain 7%	17/22/17	MT
Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes	16/22/16	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	26/22/26	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Announces Profit Distribution Proposal for 2021	29/22/29	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	28/22/28	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	27/22/27	CI
Hunan Er-Kang Pharmaceutical Co., Ltd signed equity purchase agreement to acquire Henan Yuxingkang Pharmaceutical Co., Ltd. from Shuai Fangwen and Cao Zaiyun for CNY 44 million.	28/21/28	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	27/21/27	CI
Hunan Er-Kang Pharmaceutical Co., Ltd(XSEC:300267) added to S&P Global BMI Index	20/21/20	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	26/21/26	CI
Xu Zhiqi completed the acquisition of 3.4% stake in Hunan Er-Kang Pharmaceutical Co., Ltd from Hunan Shuaijia Investment Co., Ltd.	21/21/21	CI
An unknown buyer agreed to acquire 3.4% stake in Hunan Er-Kang Pharmaceutical Co., Ltd for approximately CNY 200 million.	02/21/02	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 09, June 2021	03/21/03	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Approves Final Cash Dividend for the Year 2020	22/21/22	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2020	29/21/29	CI

Chart Hunan Er-Kang Pharmaceutical Co., Ltd

Duration

Period

Chart Hunan Er-Kang Pharmaceutical Co., Ltd

More charts

Company Profile

HUNAN ER-KANG PHARMACEUTICAL CO., LTD. is principally engaged in the research, development, production and sales of pharmaceutical excipients, finished drugs and bulk drugs. The Companyâs pharmaceutical excipients mainly consist of glycerol for medicine, sugar for medicine, ethanol for medicine, propylene glycol for medicine, as well as sodium hydroxide for medicine and others. Its bulk drugs consist of sulfadiazine, sulphaguanidine and resorcinol, among others. Its finished drugs consist of sulbenicillin sodium injections and compound liquorice tablets. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

12:00pm - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUNAN ER-KANG PHARMACEUTICAL CO., LTD	-18.69%	746M
ELI LILLY AND COMPANY	+32.36%	694B
NOVO NORDISK A/S	+30.24%	593B
JOHNSON & JOHNSON	-1.60%	371B
MERCK & CO., INC.	+20.07%	331B
ABBVIE INC.	+6.04%	290B
ASTRAZENECA PLC	+14.45%	239B
NOVARTIS AG	+10.14%	209B
ROCHE HOLDING AG	-3.23%	209B
AMGEN INC.	+9.27%	169B

Other Pharmaceuticals